Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy
Scandinavian Journal of Urology · 24.04.2026 · 61 · 148-155
DOI: 10.2340/sju.v61.45539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 24.04.2026. Verfasst von Antti Nummi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Helsinki University Hospital, Helsinki, Finland. antti.nummi@hus.fi. Hauptthemen laut MEDLINE: BCG Vaccine, Bacteriuria, Immunotherapy, Adjuvants, Immunologic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To determine whether asymptomatic bacteriuria (ABU) prior to Bacillus Calmette-Guérin (BCG) immunotherapy has an impact on the oncological results and overall tolerability of BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC). Materials and methods: We analyzed retrospectively all patients who received ≥ 1 BCG instillations as treatment of NMIBC in Helsinki University Hospital and Turku University Hospital during 2009–2018. Patients submitted urine specimen 1–7 days prior to the initiation of BCG therapy. ABU was classified as having any positive urine culture but no dysuria or fever. Our primary endpoints were 5-yr recurrence-free survival and progression-free survival. Discontinuation rate of BCG therapy was a secondary endpoint.
Results
We identified 795 patients, of whom 154 (19%) had ABU prior to the first BCG instillation. The 5-yr recurrence-free survival rates in the uninfected and bacteriuric groups were 63% (95% confidence interval [CI]: 59–67%) vs. 69% (95% CI: 62–78%), respectively (hazard ratio [HR] 0.83, 95% CI 0.60–1.14). The 5-yr progression-free survival rates were 88% (95% CI: 86–90%) vs. 89% (95% CI: 84–94%), respectively (HR 0.86, 95% CI 0.50–1.49). The 3-yr discontinuation-free survival rates were 51% (95% CI: 47–54%) vs. 51% (95% CI: 44–60%), respectively (HR 0.98, 95% CI 0.75–1.28).
Conclusion
ABU did not significantly affect BCG immunotherapy outcomes. Intravesical BCG during ABU is safe, with similar discontinuation rates, indicating very similar treatment tolerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Helsinki University Hospital, Helsinki, Finland. antti.nummi@hus.fi.
- Department of Urology, Turku University Hospital, Turku, Finland.
- Department of Urology, Tampere University Hospital, Tampere, Finland.
- Department of Urology, Helsinki University Hospital, Helsinki, Finland.
Zitieren
APA
Nummi, A., Nurminen, P., Kesti, O., Högerman, M., Ettala, O., Boström, P. J., Kaipia, A., Sairanen, J., & Järvinen, R. (2026). Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy. Scandinavian Journal of Urology, 61, 148-155. https://doi.org/10.2340/sju.v61.45539
Vancouver
Nummi A, Nurminen P, Kesti O, Högerman M, Ettala O, Boström PJ, et al. Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy. Scandinavian Journal of Urology. 2026;61:148-155. doi:10.2340/sju.v61.45539
BibTeX
@article{Nummi2026,
author = {Nummi, Antti and Nurminen, Pertti and Kesti, Olli and Högerman, Mikael and Ettala, Otto and Boström, Peter J and Kaipia, Antti and Sairanen, Jukka and Järvinen, Riikka},
title = {Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy},
journal = {Scandinavian Journal of Urology},
year = {2026},
volume = {61},
pages = {148--155},
doi = {10.2340/sju.v61.45539}
}
EUVIMED